Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M440Revenue (TTM) $M17.4Net Margin (%)-203.6Altman Z-Score-0.3
Enterprise Value $M380EPS (TTM) $-0.5Operating Margin %-205.3Piotroski F-Score3
P/E(ttm)--Beneish M-Score52.6Pre-tax Margin (%)-204.6Higher ROA y-yN
Price/Book6.010-y EBITDA Growth Rate %--Quick Ratio5.1Cash flow > EarningsY
Price/Sales25.25-y EBITDA Growth Rate %--Current Ratio5.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-8,200.0ROA % (ttm)-27.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-39.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M70.0ROIC % (ttm)-325.5Gross Margin Increase y-yY

Gurus Latest Trades with PGNX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PGNXMario Gabelli 2016-06-30 Buy $4.06 - $5.54
($4.82)
$ 6.2830%New holding25,000
PGNXKen Fisher 2016-06-30 Add$4.06 - $5.54
($4.82)
$ 6.2830%Add 0.12%140,361
PGNXKen Fisher 2015-12-31 Add$5.5 - $8.16
($6.57)
$ 6.28-4%Add 68.40%140,191
PGNXKen Fisher 2015-09-30 Buy $5.48 - $9.42
($7.67)
$ 6.28-18%New holding83,250
PGNXJulian Robertson 2015-06-30 Sold Out -1.29%$4.95 - $7.82
($6.05)
$ 6.284%Sold Out0
PGNXJulian Robertson 2014-09-30 Buy 1.8%$4.15 - $5.56
($4.99)
$ 6.2826%New holding1,290,055
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PGNX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PGNX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ISRAEL ROBERT JExecutive Vice President, Medi 2015-06-11Sell2,000$6.83-5.71view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-13Sell3,000$7-8view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-11Sell2,000$6.83-5.71view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-03Sell5,000$6.49-0.77view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-01-12Sell2,000$7.06-8.78view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-12-11Sell3,000$7.07-8.91view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-21Sell9,000$7-8view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-13Sell10,000$6.83-5.71view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-11Sell5,000$6.53-1.38view
Broadfin Healthcare Master Fun10% Owner 2014-07-21Buy1,625,436$4.640view

Quarterly/Annual Reports about PGNX:

News about PGNX:

Articles On GuruFocus.com
Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Oct 04 2010 

More From Other Websites
PROGENICS PHARMACEUTICALS INC Financials Aug 13 2016
Valeant’s Relistor Said to Draw Interest of Potential Buyers Aug 05 2016
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2016
Progenics reports 2Q loss Aug 04 2016
Progenics reports 2Q loss Aug 04 2016
Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results Aug 04 2016
Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results Aug 04 2016
Biotech Week In Review: Valeant, Progenics, Relistor and Vesneo – Valeant Pharmaceuticals Intl Inc... Jul 29 2016
Progenics Receives $50 Million Milestone Payment Following FDA Approval of RELISTOR® Tablets for... Jul 26 2016
Progenics receives $50 mln milestone payment after opioid-induced constipation drug approval Jul 26 2016
Progenics Receives $50 Million Milestone Payment Following FDA Approval of RELISTOR® Tablets for... Jul 26 2016
Progenics Pharmaceuticals Sets Second Quarter 2016 Financial Results Call for August 4 Jul 22 2016
Progenics Pharmaceuticals Sets Second Quarter 2016 Financial Results Call for August 4 Jul 22 2016
ETF’s with exposure to Progenics Pharmaceuticals, Inc. : July 21, 2016 Jul 21 2016
Why Valeant, Progenics, Ryerson, Zafgen and TerraForm Are On The Move Today Jul 20 2016
These 3 Stocks Are Rising on Big Volume -- Is It Time to Buy? Jul 20 2016
Progenics (PGNX) Stock Soars as Relistor Receives FDA Approval Jul 20 2016
Valeant Pharmaceuticals: Two for Two Jul 20 2016
Valeant (VRX) Stock Gains as FDA Approves Anticonstipation Drug Jul 20 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)